Sending a broader signal to drug makers that products tested in only one region might not pass muster, FDA advisers on Thursday (Feb. 10) overwhelmingly agreed that Eli Lilly and Innovent Biologics need to conduct U.S.-focused trials for their lung cancer drug, sintilimab, falling in line with FDA officials who had raised myriad issues that the drug was only tested in China and not in a U.S. patient population. FDA officials stressed the data are not adequate for U.S. review...